“Tracy is an extremely knowledgeable and personable finance manager. She has all the necessary qualities to run a successful finance team. She is hard working, friendly and a great listener. She would make a great addition to lead any finance team!”
About
• Exceptional analytical and quantitative skills in financial forecasting, financial…
Activity
-
With full Energy towards our targets... The medium term EHS road maps for Imerys are defined and approved, now it's time to kick off the actions…
With full Energy towards our targets... The medium term EHS road maps for Imerys are defined and approved, now it's time to kick off the actions…
Liked by Tracy Zhai
-
Each year, I look forward to attending the IFMA The Food Away from Home Association COEX because it’s a conference that brings together the brightest…
Each year, I look forward to attending the IFMA The Food Away from Home Association COEX because it’s a conference that brings together the brightest…
Liked by Tracy Zhai
-
🌟 🐾 Mayor Fur All: Pawsitively Transforming Fremont into a Better City for Pets!🐶✨ Exciting news our City of Fremont ‘s Tri-City Animal Shelter…
🌟 🐾 Mayor Fur All: Pawsitively Transforming Fremont into a Better City for Pets!🐶✨ Exciting news our City of Fremont ‘s Tri-City Animal Shelter…
Liked by Tracy Zhai
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Languages
-
English
Native or bilingual proficiency
-
Chinese
Native or bilingual proficiency
Recommendations received
1 person has recommended Tracy
Join now to viewMore activity by Tracy
-
Almost 3 years ago today, Katherine Boyle called me and said we should run a conference in Washington. She and David Ulevitch launched the American…
Almost 3 years ago today, Katherine Boyle called me and said we should run a conference in Washington. She and David Ulevitch launched the American…
Liked by Tracy Zhai
-
One year ago today, AbbVie acquired ImmunoGen. Our collective teams have made significant progress since then, receiving regulatory approval in…
One year ago today, AbbVie acquired ImmunoGen. Our collective teams have made significant progress since then, receiving regulatory approval in…
Liked by Tracy Zhai
-
Elon Musk, the world’s richest man, doesn’t just invest in innovation—he embodies it. Whether running multiple billion-dollar companies, championing…
Elon Musk, the world’s richest man, doesn’t just invest in innovation—he embodies it. Whether running multiple billion-dollar companies, championing…
Liked by Tracy Zhai
-
Fantastic start to the year with fiscal H1, 2025 results from Paul and the CSL team. It was great to see the team in Australia last week!
Fantastic start to the year with fiscal H1, 2025 results from Paul and the CSL team. It was great to see the team in Australia last week!
Liked by Tracy Zhai
-
Had a very interesting chat with Positron AI CTO Thomas Sohmers. The startup is using Altera FPGAs to make a fast LLM inference appliance, which it…
Had a very interesting chat with Positron AI CTO Thomas Sohmers. The startup is using Altera FPGAs to make a fast LLM inference appliance, which it…
Liked by Tracy Zhai
-
🌟 Exciting News! 🌟 We are thrilled to announce that EY has remained global IPO leader for an incredible 13 consecutive years! At EY, we take pride…
🌟 Exciting News! 🌟 We are thrilled to announce that EY has remained global IPO leader for an incredible 13 consecutive years! At EY, we take pride…
Liked by Tracy Zhai
-
I'm honored and humbled to be recognized by USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. I look forward to celebrating with my…
I'm honored and humbled to be recognized by USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. I look forward to celebrating with my…
Liked by Tracy Zhai
-
At Andreessen Horowitz, I’m fortunate to work with a number of groundbreaking companies and I couldn’t be more thrilled to share that I’ve joined the…
At Andreessen Horowitz, I’m fortunate to work with a number of groundbreaking companies and I couldn’t be more thrilled to share that I’ve joined the…
Liked by Tracy Zhai
-
We never know who will end up hoisting the Vince Lombardi Trophy, but one thing I can always bet on is the winning partnership between PepsiCo and…
We never know who will end up hoisting the Vince Lombardi Trophy, but one thing I can always bet on is the winning partnership between PepsiCo and…
Liked by Tracy Zhai
-
Just 2 weeks after Mitesh Agrawal joined us as CEO, we are very excited to announce that Positron AI has closed $23.5M in seed funding, with new…
Just 2 weeks after Mitesh Agrawal joined us as CEO, we are very excited to announce that Positron AI has closed $23.5M in seed funding, with new…
Liked by Tracy Zhai
-
I am working with a team of executives with past experience at Curium. They have brought 5 radio isotopes to market and are developing a novel pb-212…
I am working with a team of executives with past experience at Curium. They have brought 5 radio isotopes to market and are developing a novel pb-212…
Liked by Tracy Zhai
-
Association For Corporate Growth - ACG Silicon Valley Young Executives Circle - Night out at the San Jose Sharks at SAP Center at San Jose Yvonne…
Association For Corporate Growth - ACG Silicon Valley Young Executives Circle - Night out at the San Jose Sharks at SAP Center at San Jose Yvonne…
Liked by Tracy Zhai
Other similar profiles
Explore more posts
-
Los Angeles Biotech Networks
#ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer https://lnkd.in/gCx3byzU As companies increasingly look to combinations to boost the efficacy of KRAS therapies, a Phase 2 study is offering some of the first clinical evidence for combining KRAS and EGFR in frontline lung cancer. On [...]
-
Los Angeles Biotech Networks
CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager https://lnkd.in/gMW56vQD CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash. In order to focus its resources on its lead antibody-drug conjugate (ADC) and an array [...]
-
San Francisco Biotech Networks
SFBN Feed: Is pharma still fearful of the Inflation Reduction Act? https://lnkd.in/g5wiVXEN Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good summer morning! Today, we discuss the big Medicare price negotiations (and the not-entirely-meaningful [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
San Francisco Biotech Networks
SFBN Feed: Kardigan Launches with Industry-Leading Team to Modernize Cardiovascular Drug Development with Late-Stage Portfolio of Personalized Medicines https://lnkd.in/gZT-5c7A SAN FRANCISCO & PRINCETON, N.J.–(BUSINESS WIRE)–Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
BioprocessUpdates
📢 Cambrex Partners with Lilly to Accelerate Drug Development! 🚀 Cambrex has partnered with Eli Lilly to enhance clinical development for biotech collaborators. They will provide drug substance, product, and analytical services through Lilly's Catalyze360-ExploR&D. 🔬 Cambrex's Longmont facility will lead these efforts, utilizing its capabilities for efficient drug development, including GMP production. This collaboration aims to expedite product development for emerging therapies. #BioprocessUpdates #Cambrex #EliLilly #Biotech #Pharmaceuticals #DrugDevelopment #ClinicalTrials #GMP #Collaboration #BiotechInnovation #PharmaNews #Healthcare #Manufacturing #EmergingTherapies #Catalyze360 #ExploR&D ▷ Read the full article here: 📎 https://lnkd.in/d_PEZc6J
-
Los Angeles Biotech Networks
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration https://lnkd.in/gKNBbHPr Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News
-
Los Angeles Biotech Networks
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration https://lnkd.in/gKNBbHPr Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option [...]
-
Andrew Mears
CDMO Nucleus RadioPharma reveals expansions at two sites that will "significantly improve" market access to promising cancer treatments. 🏗️ The upgrades at sites in Mesa, #Arizona and Springhouse, #Pennsylvania will give each facility research, development and commercial production capabilities, boosting capacity by 200%. The expansions are expected to be completed by the end of 2026 and will create around 100 jobs overall. 💉 The upgrades will allow more patients to receive radiopharmaceuticals, which have a limited shelf-life, according to Nucleus. 💬 "To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them," Nucleus RadioPharma CEO Charles Conroy, RPh, MBA said in a release. "Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%." #CDMO #Radiopharmaceuticals #Radiopharma
-
The Center for Biosimilars
Big news for patients & competition in the biosimilar space!📰 Costco now offers Celltrion's adalimumab biosimilar, Amgen sues Samsung Bioepis, & GlycoNex advances its denosumab biosimilar! What does this mean for patients & the future of biosimilars?💡 Read the full story for the scoop! https://lnkd.in/eA22GK4t
-
San Francisco Biotech Networks
SFBN Feed: Arcellx and Gilead seek to unseat J&J-Legend in multiple myeloma https://lnkd.in/g_9CQUG2 SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson & Johnson. New results from a pivotal study of [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
California Life Sciences (CLS)
🌟 We're thrilled to spotlight our prestigious Pantheon Biopharma Award, honoring innovation and excellence in the biopharmaceutical industry. Presented to a biotech or pharmaceutical company that has made groundbreaking advancement and contribution to the California life sciences sector in the prior year. 🧬 Award Criteria: Our rigorous selection process evaluates key factors such as product launch, scientific breakthrough, facility openings, employee growth, or partnering deals/acquisitions that will foster future advancements for the industry. 🏆 Past Winners: Previous awardees have made significant contributions to biopharma development, demonstrating leadership and transformative impact in the field. Past distinguished winners include: BioMarin Pharmaceutical Inc. (2023) and Coherus BioSciences (2022). 🔗 Learn more about the award and our methodology: https://bit.ly/4fjq1Fx Join us in celebrating those who push the boundaries of science and healthcare! #Biopharma #Innovation #CaliforniaLifeSciences #Pantheon
-
San Diego Biotechnology Network
SDBN Feed: Belharra Therapeutics sticks with lead programs, trims workforce by 40% https://lnkd.in/guTbHqbS San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as Bayer-acquired Vividion, made the internal announcement [...]
-
Pharma Now - Empowering Pharma Leadership
Pharma Industry News Flash ⚡💊 1. Cue Biopharma shifts focus to autoimmune initiatives, reducing operational costs by 25%. 🧬🔄 2. Laura Hamill joins Jazz Pharmaceuticals' Board, bringing extensive industry expertise. 👨💼💼 3. Summit Therapeutics, Inc. and MD Anderson Cancer Center advance Ivonescimab for cancer treatment, enhancing therapeutic options. 🧪🚀 4. Windtree Therapeutics, Inc. advances #Istaroxime clinical trials, aiming to improve heart failure treatments. ❤️🔬 Stay informed with Pharma Now! Read more news at - https://lnkd.in/dh36nZ8Y What are your thoughts on these updates? Share your opinions in the comments below! 💬 #PharmaNow #pharmanews #healthcareinnovation #globalpharma #autoimmune #clinicaltrials #leadership #cancertreatment #heartfailure
-
Fintiede Solutions Ltd
🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper
-
Los Angeles Biotech Networks
EQBMED launches trial sites tool to assess performance and boost diversity https://lnkd.in/g5vKvi3a The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an assessment tool for clinical trial sites to evaluate their ability to perform diverse trials and chart out a path toward improvement in [...]
-
BioDataStudio
🔬 ProfoundBio Raises $112M for Next-Gen Cancer Therapies TL;DR: • Seattle biotech startup secures major funding for ADC development • Lead candidate Rina-S entering Phase 2 trials for ovarian/endometrial cancers • Novel hydrophilic linker technology shows promise • Global ADC market projected to reach $40.3B by 2029 ProfoundBio, led by former Seagen veterans, just secured $112M in funding to advance their innovative antibody-drug conjugate (ADC) pipeline. The round was led by Ally Bridge Group, with T. Rowe Price and RA Capital Management participating. What sets them apart? Their proprietary hydrophilic linker technology - dubbed the company's "secret sauce" by CFO/COO Erin Lavelle - enhances tumor-targeting precision. Key developments: • Rina-S targeting folate receptor α in Phase 2 • Two additional ADCs in Phase 1 for kidney/breast cancers • Fourth dual-pronged ADC entering trials in 2024 • Potential to treat patients with lower FRα expression levels Despite the challenging funding landscape for cancer drug startups, this raise signals strong investor confidence in ADC technology's future. 💭 What are your thoughts on the evolving ADC landscape? Are we entering a new era of precision cancer therapeutics? #Biotech #CancerResearch #DrugDevelopment #Innovation #ADC #intelligencesimplified #pharma #biotech #biodatastudio
-
BioSpace
On May 8 join DEIB leaders from MassBio, California Life Sciences (CLS), Eli Lilly and Company and Takeda as we explore changing attitudes in the life sciences workforce, if organizations are adjusting either their DEIB or communication strategies, and how evolving philosophies around DEIB are impacting human resources and talent acquisition activities. Register below! #diversity #lifesciences #insights #biospace https://hubs.li/Q02vXs3n0
-
Pharma Industrial India
Innovent Biologics, Inc. announced that China's NMPA-National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. #healthcare #PharmaIndustrialIndia
-
Envita Medical Centers - Cancer and Lyme Disease Facility
🌟 For 25 years, Envita Medical Centers in Scottsdale, Arizona, has been a leader in precision cancer care. Unlike standard oncology, we take an in-depth approach by analyzing each patient’s unique genetic profile to create a targeted treatment plan, tailored for their specific needs – no matter the type or stage of cancer. At Envita, we don’t just manage cancer; we aim to shut it down at its core, improving quality of life and reducing treatment toxicity. 🌿 Because every patient deserves a truly personalized approach to their health. Ready for a different path to healing? Discover more at Envita Medical Centers. #PrecisionOncology #CancerTreatment #EnvitaMedicalCenters #CancerCare #PersonalizedMedicine #TargetedTherapy
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More